NX Prenatal Inc.
LOUISVILLE, KY · Founded 2013 · CIK 0001721472 · Medtech · Private
Non-invasive prenatal blood tests for maternal and fetal health assessment
nxprenatal.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $5.8M
- 4 Form D · Aug 2023
- 38 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 18
- 3 granted · 15 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $427,536 | |
| Private capital raised | Form D · SEC | $2,135,583 | |
| Private capital raised | Form D · SEC | $72,000 | |
| Private capital raised | Form D · SEC | $3,125,071 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1122 | Oralucent, Inc. | — | $2.3M |
| 1123 | TEAL HEALTH INC | — | $45M |
| 1124 | SENOGUARD, INC. | — | — |
| 1125 | NX Prenatal Inc. | — | $5.8M |
| 1126 | iNanoBio, Inc. | — | $3.3M |
| 1127 | ZeoVation, Inc. | — | $780K |
| 1128 | NOTA Laboratories, Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- David AdairDirector
- DAVID ADAIRDirector
- KEVIN BRAMERDirector
- Brian BrohmanDirector · Executive Officer
- BRIAN BROHMANDirector · Executive Officer
- Mary Lake PolanDirector
- Alan MackDirector
- ALAN MACKDirector
- Gail PageDirector · Executive Officer
- GAIL PAGEDirector · Executive Officer
- Robert SaundersDirector
- ROBERT SAUNDERSDirector
Patents
- Detection Of Microparticle-associated Proteins Associated With Spontaneous Preterm Birthapplication
- Detection Of Microparticle-associated Proteins Associated With Spontaneous Preterm Birthgranted
- Use Of Circulating Microparticles To Stratify Risk Of Spontaneous Preterm Birthapplication
- Tandem-paired Column Chemistry For High-throughput Proteomic Exosome Analysisapplication
- Systems And Methods Of Using Machine Learning Analysis To Stratify Risk Of Spontaneous Preterm Birthapplication
- Treatment Of Spontaneous Preterm Birthgranted
- Treatment Of Spontaneous Preterm Birthgranted
- Biomarkers Of Preterm Birthapplication
- Tandem-paired Column Chemistry For High-throughput Proteomic Exosome Analysisapplication
- Use Of Circulating Microparticles To Stratify Risk Of Spontaneous Preterm Birthapplication
- Use Of Circulating Microparticles To Stratify Risk Of Spontaneous Preterm Birthapplication
- Tandem-Paired Column Chemistry for High Throughput Proteomic Exosome Analysisapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.